MP
ASBPW

Mangrove Partners’s Aspire Biopharma Warrant ASBPW Stock Holding History

Mangrove Partners’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-62,605
Closed -$652K – 180
2023
Q2 		$652K Hold
62,605
– – 0.05% 161
2023
Q1 		$657K Sell
62,605
-2,100
-3% -$139 0.04% 185
2022
Q4 		$666K Buy
+64,705
New +$4.35K 0.04% 260

Other funds holding ASBPW

AC
Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 26.7% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.5% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Mangrove Partners's ASBPW Position: Q3 2023 in Review

Mangrove Partners sold out of Aspire Biopharma Warrant (ASBPW) in Q3 2023, closing a stake of 62,605 shares — an estimated $652K sold.

Mangrove Partners first reported a position in ASBPW in Q4 2022 and held it in 3 quarters. The position peaked at $666K in Q4 2022. 39 funds tracked by Wall St. Rank hold ASBPW as of Q3 2023.

  • Mangrove Partners reported no remaining Aspire Biopharma Warrant position as of Q3 2023 after selling out during the quarter.
  • Mangrove Partners sold 62,605 Aspire Biopharma Warrant shares in Q3 2023, an estimated $652K.
  • Mangrove Partners first reported a position in Aspire Biopharma Warrant in Q4 2022 and held it in 3 quarters.
  • Mangrove Partners's Aspire Biopharma Warrant position peaked at $666K in Q4 2022.
  • 39 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q3 2023.

Based on Mangrove Partners's 13F filing for Q3 2023, filed 14 Nov 2023.